The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
Open accessAbstract
BACKGROUND Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality. There is no known effective therapy. METHODS We conducted a randomized, double-blind, clinical trial in healthy adults inoculated with RSV. Participants received the oral nucleoside analogue ALS-008176 or placebo 12 hours after confirmation of RSV infection or 6 days after inoculation. Treatment was administered every 12 hours for 5 days. Viral load, disease severity, resistance, and safety were measured throughout the 28-day study period, with measurement beginning before inoculation. The primary end point was the area under the curve (AUC) for viral load, which was assessed immediately before administration of the first dose through the 12th day after inoculation in participants infected with RSV. RESULTS A total of 62 participants received placebo or one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9 maintenance doses of 500 mg (group 1), 1 loading dose of 750 mg followed by 9 maintenance doses of 150 mg (group 2), or 10 doses of 375 mg (group 3). In the 35 infected participants (23 of whom were treated with ALS-008176), the AUCs for viral load for groups 1, 2, and 3 and the placebo group were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equivalents × hours per milliliter, respectively (P≤0.001). The time to nondetectability on polymerase-chain-reaction assay (P<0.001), the peak viral load (P≤0.001), the AUC for symptom score (P<0.05), and the AUC for mucus weight were lower in all groups receiving ALS-008176 than in the placebo group. Antiviral activity was greatest in the two groups that received a loading dose--viral clearance was accelerated (P≤0.05), and the AUC for viral load decreased by 85 to 88% as compared with the placebo group. Within this small trial, no viral rebound or resistance was identified. There were no serious adverse events, and there was no need for premature discontinuation of the study drug. CONCLUSIONS In this RSV challenge study, more rapid RSV clearance and a greater reduction of viral load, with accompanying improvements in the severity of clinical disease, were observed in the groups treated with ALS-008176 than in the placebo group. (Funded by Alios BioPharma; ClinicalTrials.gov number, NCT02094365.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773
Cited by
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Respiratory syncytial virus infection in adults
Nam, H. H., & Ison, M. G. (2019) · BMJ · doi:10.1136/bmj.l5021 · Cited by 332
Huang, H.-S., Tsai, C.-L., Chang, J., Hsu, T.-C., Lin, S., & Lee, C.-C. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.11.018 · Cited by 277
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Metadata
- Authors
- DeVincenzo, J. P., McClure, M. W., Symons, J. A., Fathi, H., Westland, C., Chanda, S., Lambkin-Williams, R., Smith, P., Zhang, Q., Beigelman, L., Blatt, L. M., & Fry, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-19
- Volume
- 373
- Issue
- 21
- Pages
- 2048-2058
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2334783812
- Cited by
- 234
- References
- 1
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. https://app.cochat.ai/papers/10.1056/nejmoa1413275
- The paper
- DeVincenzo, J. P., McClure, M. W., Symons, J. A., Fathi, H., Westland, C., Chanda, S., Lambkin-Williams, R., Smith, P., Zhang, Q., Beigelman, L., Blatt, L. M., & Fry, J. (2015). Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1413275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.